Impact BioMedical announces completion of IPO

Impact BioMedical announced the completion of its Initial Public Offering. Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential. Frank D. Heuszel, CEO of Impact BioMedical, commented, “The significant participation of our investors underscores their confidence in our mission and the innovative healthcare solutions we are developing. Their support is a testament to the value they see in our work and our potential to make a meaningful impact on human health.”